Loading patent…
AssigneesMercian Corporation, Eisai R&D Management Co., Ltd.
InventorsAkifumi Okuda, Satoshi Yamamoto, Takashi Sakai, Susumu Takeda, Takashi Nakashima, Katsura Kaneko, Tomohiro Sameshima, Taira Kato, Naoto Kawamura
Estimating the term…
The present invention provides a novel method of producing the 12-membered ring macrolide compound 11107D having an antitumor activity by biological transformation. Starting material which is the 12-membered ring macrolide compound 11107B represented by the formula (I) is incubated in the presence of a strain belonging to the genus Mortierella, the genus Streptomyces or the family Micromonosporaceae (for example, Streptomyces sp. AB-1704 strain (FERM BP-8551)), each of which has the ability of transforming the 12-membered ring macrolide compound 11107B into a 11107D substance represented by the formula (II), or a preparation of its cultured mycelia and oxygen, and then 11107D substance which is a target material is collected from the treating solution.
A method of producing the macrolide compound 11107D represented by the formula (II):
Streptomyces sp. AB-1704 strain (FERM BP-8551) having the ability of transforming the macrolide compound 11107B represented by the above formula (I) into the macrolide compound 11107D represented by the above formula (II).
Mortierella sp. F-1529strain (FERMBP-8547) or F-1530 strain (FERM BP-8548) having the ability of transforming the macrolide compound 11107B represented by the above formula (I) into the macrolide compound 11107D represented by the above formula (II).
AB-1896 strain (FERM BP-8550) having the ability of transforming the macrolide compound 11107B represented by the above formula (I) in to the macrolide compound 11107D represented by the above formula (II).
Dependencies are inferred from the claim text.